Parkinson research hub

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)

This study is testing a new medicine, NEU-411, for people recently diagnosed with Parkinson's disease. Researchers want to see if it's safe and helps with symptoms, using a special app to measure changes over about a year.